Cochrane Review Finds No Clear Motor Recovery Benefit From Levodopa After Stroke
A review of 12 trials found no clear movement benefit from dopamine drugs after stroke. The strongest trials showed essentially no improvement.
Summary
Can medicines that boost dopamine help restore movement after a stroke? A Cochrane review examined 12 randomized trials involving 1,860 participants, mostly testing levodopa alongside rehabilitation. Overall, the researchers found no clear improvement in movement compared with placebo or usual care. Results varied widely, but the two trials judged most reliable, involving 1,025 participants, showed essentially no average benefit. Serious adverse events occurred at similar rates, although the evidence was too uncertain to establish equivalent safety. The findings do not support routinely adding these drugs solely to improve movement after stroke. They do not address prescribing for another established condition, such as Parkinson's disease. Evidence quality was low or very low, and future studies could identify benefits in particular patient groups. This summary is based on the abstract only.
Detailed Summary
Stroke can leave lasting difficulties with walking, balance, and everyday movement, making recovery central to independence and healthy aging. Drugs that increase dopamine activity have been proposed as a way to strengthen rehabilitation. A new Cochrane review found no convincing evidence that these medicines improve movement after stroke.
Researchers analyzed 12 randomized trials involving 1,860 participants whose average ages across studies ranged from 55 to 78 years. Eleven trials tested levodopa, and one tested ropinirole, a drug that stimulates dopamine receptors. Participants received comparable rehabilitation, with the comparison groups receiving placebo or usual care. Searches covered evidence through November 2025.
Across six trials with movement scores, the combined estimate was highly uncertain, and results varied substantially between studies. More informative was an analysis restricted to two trials judged at low risk of bias. Together including 1,025 participants, these trials showed essentially no average benefit. Two trials assessing favorable movement outcomes also found no clear advantage, with estimated success rates of 54 percent with medication versus 58 percent in comparison groups.
Serious adverse events were assessed in six trials involving 1,281 participants. Estimated rates were similar: about 31 percent with medication and 30 percent in comparison groups. However, uncertainty means these results do not establish equivalent safety. Other outcomes, including disability, daily activities, quality of life, death, and recurrent stroke, showed no notable differences.
For patients and clinicians, this review does not support routinely adding these drugs solely to improve movement after stroke. It does not address treatment for an existing condition such as Parkinson's disease. Confidence in the overall evidence was low or very low because of inconsistent findings, missing data, and imprecise estimates. This summary is based on the abstract only. Further research could clarify whether particular patient groups benefit, but a benefit has not yet been reliably demonstrated.
Key Findings
- Twelve randomized trials involving 1,860 participants found no clear motor recovery benefit from levodopa or dopamine agonists after stroke.
- The two lowest-bias trials, involving 1,025 participants, showed essentially no average improvement in movement scores.
- Serious adverse event rates were similar, but low-certainty evidence cannot establish equivalent safety.
- The evidence does not support routinely adding these drugs solely to improve movement after stroke.
Methodology
This Cochrane systematic review included 12 randomized trials comparing levodopa or ropinirole with placebo or usual care, with equivalent rehabilitation between groups. Searches extended through November 2025; reviewers used random-effects meta-analysis, independent risk-of-bias assessments, and GRADE evidence ratings.
Study Limitations
This summary is based on the abstract only. Evidence certainty was low or very low because of inconsistent findings, substantial heterogeneity, missing numerical data, and imprecise estimates. Eleven trials tested levodopa and only one tested ropinirole, limiting conclusions about other dopamine agonists or specific patient subgroups.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: